The dust-up involving Dr. Charles Nemeroff and Dr. Thomas Insell, director of NIMH shines a light on NIH leaders whose failure to enforce federal disclosure requirements is brushed off with excuses so untenable they have the ring of theater of the absurd.
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
Legislation is needed to ensure that conflicts of interest rules in medicine are enforced. One method for reigning in the abuse is to prohibit government grant awards to any researcher who violates financial conflict of interest rules.
Business Week reports: "From 1986 to 2003 the number of nonsurgical cardiac procedures, such as propping open arteries with wire-mesh stents, rose twelve fold, according to the American Heart Association.
Latest Huckstersm: Surgical Implants for Depression – NYT Sat, 21 May 2005 The FDA was supposed to protect the public from snake oil hucksterism. It is appalling to note how far the FDA’s approval process for drugs and devices has veered away from it’s 1962 standards of evidence-based medicine. [1]…
Senate Finance Committee Investigating FDA brain stimulation device approval – WSJ Thu, 19 May 2005 Another major scandal is erupting about FDA’s approval decisions that contradict its medical officer’s safety concerns. The Senate Finance Committee is investigating what led the FDA to suddenly reverse its disapproval of Cyberonics’ brain stimulation…
Lilly's aggressive marketing of Xigris does indeed epitomize the worst ofthis industry's mission.
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
A follow-up to news reports about the conflict of interest scandal that has engulfed not only Dr. Charles Nemeroff, former president and editor in chief of the official journal of the American College of Neuropsychopharmacology, but the College itself.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
The Wall Street Journal and Bloomberg News report about a case involving Neuropsychopharmacology, the official journal of the American College of Neuropsychopharmacology (ACNP) that will likely go down in history as psychiatry’s Watergate.
